- Trial phase
- Approved (Phase 3 / registrational Phase 2 for additional indications)
- Time to market
- Already marketed (first FDA approval April 2021). Potential label expansion in dMMR/MSI-H rectal cancer would follow AZUR-1 data (H2 2026) and subsequent BLA filing.
- Why 5/10
- Jemperli is already FDA-approved and generating >$1B in run-rate revenue, so there is no PDUFA binary. The next hard dated catalyst is the AZUR-1 registrational Phase 2 readout in dMMR/MSI-H rectal cancer, expected H2 2026. At a ~$52B market cap diversified pharma like GSK (~$34B revenue), even a strong readout moves the stock a modest 2-4%. Score capped at 5 per the rubric for approved drugs with no pending regulatory decision.
Watch for AZUR-1 Phase 2 registrational data in H2 2026, a positive readout (extending the 100% cCR rate seen in the MSK-collaboration study) could lead to an FDA filing for rectal cancer and support the ~$2.5B+ peak sales consensus. Be aware of the AnaptysBio royalty dispute going to trial in July 2026, which could alter Jemperli's economics. For a diversified phyla stock like GSK, Jemperli is a growth driver in oncology but not a stand-alone thesis.
Price Chart
Executive Summary
Jemperli (dostarlimab) is GSK's PD-1 checkpoint inhibitor immunotherapy, first approved by the FDA in April 2021 for dMMR endometrial cancer and expanded in August 2024 to cover all adult patients with primary advanced/recurrent endometrial cancer, including the MMRp/MSS tumors that represent ~75% of cases. It generated ~$785M in the first nine months of 2025 and is on track to exceed $1B in annual sales, with consensus peak sales above $2.5B by 2030. The drug faces intense competition from Merck's Keytruda and AstraZeneca's Imfinzi, and GSK has suffered setbacks in ovarian cancer and NSCLC trials. The next major catalyst is the AZUR-1 Phase 2 registrational readout in dMMR/MSI-H rectal cancer (H2 2026), where an earlier MSK-collaboration study showed an unprecedented 100% clinical complete response rate. A concurrent royalty dispute with AnaptysBio (trial set for July 2026) adds headline risk.
How It Works
Jemperli is an immunotherapy, a lab-made antibody that blocks a protein called PD-1 on immune cells (T-cells). PD-1 normally acts as an "off switch" that cancer cells flip to avoid being attacked. By blocking that switch, Jemperli keeps the immune system active against cancer cells. It is in the same class as Merck's Keytruda and Bristol Myers' Opdivo.
Trial Status
Jemperli is commercially approved in the US and EU for endometrial cancer (multiple lines). The registrational Phase 2 AZUR-1 trial (dMMR/MSI-H rectal cancer) is fully enrolled with data expected H2 2026. Phase 3 AZUR-2 (colon cancer) and JADE (head & neck cancer) trials are ongoing (readouts H2 2028). The Phase 3 RUBY trial in endometrial cancer met its dual primary endpoints with statistically significant OS benefit. The Phase 3 FIRST trial in ovarian cancer and ZEAL-1L in NSCLC missed primary endpoints.
The Two-Sided Case
Upcoming Catalysts
- AZUR-1 registrational Phase 2 pivotal data readout in dMMR/MSI-H rectal cancer, expected H2 2026.
- AnaptysBio royalty dispute trial, scheduled July 14, 2026 (Delaware Chancery Court).
- AZUR-2 Phase 3 colon cancer data, expected H2 2028.
- Potential FDA BLA submission for rectal cancer label expansion (contingent on AZUR-1 data).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GSK plc 6-K GSK ·Originating report